- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04718038
Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer
A Clinical Study of Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients volunteered to participate in this study and signed informed consent.
- Patients with wild-type KRAS,NRAS and BRAF V600E metastatic colorectal adenocarcinoma confirmed by histology and genetic testing.
- Patients with metastatic colorectal cancer (stage IV) confirmed by imaging (CT/MRI) with measurable lesions (according to RECIST 1.1 criteria)
- Patients who had previously received first-line standard chemotherapy in combination with cetuximab, or/and maintenance therapy with cetuximab for disease progression.The standard treatment regimens include XELOX, FOLFOX, and FOLFIRI.
5.18-70 years old ;ECOG PS score: 0~1;Life expectancy ≥ 12 weeks. 6. Provide histological specimens for secondary detection: primary lesion or metastatic lesion.
7.The main organ function meets the following criteria within 7 days before treatment:
(1)Blood routine examination criteria (without blood transfusion within 14 days): Hemoglobin (HB) ≥ 90g / L; The absolute value of neutrophils (ANC) ≥ 1.5 × 109 / L; Platelet (PLT) ≥ 80 × 109 / L; (2) Biochemical examinations must meet the following criteria: Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN); Alanine aminotransferase (ALT) Aspartate aminotransferase (AST) ≤ 2.5 * ULN; serum creatinine (Cr) ≤ 1.5 * ULN or creatinine clearance (CCr) ≥ 60ml / min; (3) Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ normal low limit (50%).
8.Women of childbearing age should agree to use contraceptives (such as intrauterine devices, contraceptives or condoms) during the study period and within 6 months after the end of the study; negative serum or urine pregnancy test within 7 days prior to study enrollment and must be non-lactating patients; men should agree to patients who must use contraception during the study period and within 6 months after the end of the study period.
Exclusion Criteria:
- Exceeding or currently suffering from other malignant tumors within 5 years, except for cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (in situ carcinoma) And T1 (tumor infiltrating basement membrane)].
- Radiation therapy on tumor target was performed within 4 weeks before enrollment.
- Unmitigated toxic reactions higher than CTC AE(4.0) grade 2 or above due to any prior treatment, excluding alopecia and neurotoxicity ≤ grade 2 due to oxaliplatin.
Any severe and/or uncontrolled disease, including:
- patients with hypertension who are not well controlled by antihypertensive drug (systolic blood pressure ≥150 mmHg, diastolic blood pressure ≥100 mmHg).
- with grade I or higher myocardial ischemia or myocardial infarction, arrhythmia (including QTc ≥ 480ms) and ≥ grade 2 congestive heart failure (New York Heart Association (NYHA) classification).
- Severe or uncontrolled disease or active infection (≥CTCAE grade 2 infection), which the investigator believes may increase the risk associated with study participation, study drug administration, or affect the subject's ability to receive study medication.
- Renal failure requires hemodialysis or peritoneal dialysis.
- a history of immunodeficiency, including HIV-positive or other acquired, congenital immunodeficiency disease, or a history of organ transplantation.
- Patients with diabetes who have poor glycemic control (fasting blood glucose (FBG) > 10 mmol/L); subjects with active, known or suspected autoimmune diseases. Subjects with type 1 diabetes, residual hypothyroidism caused by autoimmune thyroiditis requiring hormone replacement therapy, and skin diseases that do not require systemic treatment (such as vitiligo, psoriasis or alopecia) can be enrolled.
- patients with seizures and requiring treatment.
- Patients with gastrointestinal diseases such as intestinal obstruction (including incomplete intestinal obstruction) or those who may have caused gastrointestinal bleeding, perforation or obstruction.
- Patients who underwent surgical treatment, incisional biopsy or significant traumatic injury within 28 days prior to enrollment.
- In the 4 weeks prior to enrollment, patients with any bleeding event ≥ CTCAE 3 have unhealed wounds, ulcers or fractures.
- Overactive/venous thrombosis events within 3 months, such as cerebrovascular accidents (including transient ischemic attacks), deep static Pulmonary thrombosis and pulmonary embolism.
- those who have a history of psychotropic substance abuse and are unable to quit or have a mental disorder.
- Patients with brain metastases.
- Patients who have participated in other clinical trials of anti-tumor drugs within four weeks.
- According to the investigator's judgment, there is a concomitant disease that seriously harms the patient's safety or affects the patient's completion of the study.
- Cannot perform biopsy to provide histological specimens.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival(PFS)
Time Frame: 2 years
|
The time from randomization to documented disease progression or death from any cause
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survial(OS)
Time Frame: 2 years
|
The time from randomization to death from any cause
|
2 years
|
ORR
Time Frame: 2 years
|
The percentage of complete or partial responses
|
2 years
|
Safety
Time Frame: 2 years
|
assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events [version 3.0]
|
2 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HNCH-GI-100
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wild-type KRAS,NRAS and BRAF V600E Metastatic Colorectal Cancer
-
University of UtahTerminatedKRAS and NRAS Wild-type Colorectal CancerUnited States
-
Elicio TherapeuticsRecruitingColorectal Cancer | Pancreatic Ductal Adenocarcinoma | KRAS G12D | KRAS G12R | NRAS G12D | NRAS G12R | KRAS G12V | KRAS G12C | KRAS G12A | KRAS G12S | KRAS G13D | NRAS G12V | NRAS G12C | NRAS G12SUnited States
-
Karen-Lise Garm SpindlerCompletedColorectal Cancer Metastatic | KRAS Gene Mutation | Circulating Tumor DNA | BRAF Gene Mutation | NRAS Gene Mutation | Epidermal Growth Factor Receptor InhibitorDenmark
-
University Health Network, TorontoCompletedColorectal Cancer | KRAS Wildtype | NRAS Wildtype | BRAF WildtypeCanada
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC... and other conditionsUnited States
-
Pierre Fabre MedicamentCompletedMelanoma | BRAF V600E Unresectable or Metastatic Melanoma | BRAF V600E Metastatic NSCLCChina
-
Pierre Fabre MedicamentPfizer; Merck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co. LtdCompletedBRAF V600E-mutant Metastatic Colorectal CancerFrance, Italy, United States, Spain, United Kingdom, Belgium, Austria, Japan, Netherlands
-
Pierre Fabre MedicamentClinactCompletedMetastatic Colorectal Cancer | BRAF V600E Mutation PositiveFrance, United Kingdom, Spain, Belgium, Germany, Italy, Austria
-
Pierre Fabre MedicamentMerck KGaA, Darmstadt, GermanyActive, not recruitingMetastatic Colorectal Cancer | BRAF V600EChina
-
UNICANCERPierre Fabre MedicamentRecruitingMetastatic Colorectal Cancer | BRAF V600E Mutation PositiveFrance
Clinical Trials on Cetuximab combind mFOLFOX6/FOLFIRI
-
Ruijin HospitalXiangya Hospital of Central South University; Chinese PLA General Hospital; West... and other collaboratorsNot yet recruiting
-
Ruijin HospitalHenan Cancer Hospital; Second Affiliated Hospital, School of Medicine, Zhejiang... and other collaboratorsUnknownColorectal Cancer
-
Xu jianminUnknownNeoplasm Metastasis | Liver Neoplasms | Colorectal NeoplasmsChina
-
Fudan UniversityRecruitingColorectal CancerChina
-
Fujian Cancer HospitalNot yet recruitingAdvanced Colorectal Cancer
-
Fudan UniversityNot yet recruiting
-
Mirati Therapeutics Inc.Active, not recruitingMetastatic Colorectal Cancer | Advanced Colorectal CancerUnited States, Denmark, Finland, Italy, Spain, Belgium, Romania, Taiwan, Thailand, France, Germany, Korea, Republic of, China, Malaysia, Hong Kong, Australia, Austria, Puerto Rico, Singapore, Canada, Portugal, Poland, Greece, United Kingdom and more
-
Zhou FuxiangXiangya Hospital of Central South University; Henan Cancer Hospital; Hubei Cancer... and other collaboratorsRecruitingFruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal CancerMetastatic Colorectal CancerChina
-
West China HospitalFirst Affiliated Hospital of Chongqing Medical UniversityRecruitingColo-rectal Cancer | Capecitabine | CetuximabChina
-
Sofia Perea, Director Clinical Trials Unit.UnknownColorectal Cancer MetastaticSpain